Xcout IntelEikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Subscribe to see Eikon Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Eikon Therapeutics, Inc. at a glance
Eikon Therapeutics, Inc. is a biotech company headquartered in Millbrae, United States. It is publicly listed (EIKN) with a market capitalisation of $408.2M. Xcout tracks 29 named people at Eikon Therapeutics, Inc., including Roger Perlmutter (Chairman, President & CEO). Xcout recorded 63 job postings from Eikon Therapeutics, Inc. in the last 90 days, naming tools such as SAP, SuccessFactors.
Eikon Therapeutics, Inc. leadership
- Roger PerlmutterChairman, President & CEO
- Roger M PerlmutterChief Executive Officer
- Michael A KlobucharChief Operating Officer
- Mike KlobucharChief Operating Officer
- Alfred BowieChief Financial Officer
- Alfred Lloyd Bowie Jr.Treasurer & CFO
23 more named people on record for Eikon Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Eikon Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $350.7M | 8 named | |
| Series D | $148M | 8 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Eikon Therapeutics, Inc.
Xcout recorded 63 job postings from Eikon Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Eikon Therapeutics, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Eikon Therapeutics, Inc.'s hiring signals →
Recent Eikon Therapeutics, Inc. news
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
- IPOEikon plans IPO to bankroll clutch of clinical cancer drugs
4 corporate events on record, with sources — see the full timeline →
Hiring vs the trend
Based on 28 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Eikon Therapeutics, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Investors
Tech stack
Eikon Therapeutics, Inc. competitors
A few of Eikon Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Parabilis Medicines is a biopharmaceutical company that develops ultra-tunable peptide therapeutics utilizing its proprietary Helicon platform. The company focuses on creating novel medicines to target historically undruggable conditions, primarily addressing cancer and other serious diseases with critical medical needs.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Aelin Therapeutics is a biopharmaceutical company based in Leuven, Belgium, that develops peptide-based novel drug modalities and biotherapeutic technology platforms designed to induce functional knockdown of target proteins through protein aggregation.
Get Eikon Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Eikon Therapeutics, Inc. in Xcout Intel
- 29 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access